Application of Arsenic Trioxide-Based Combined Sequential Chemotherapy in Recurrent Resistant and Refractory Ovarian Cancers: A Single-Center, Open Phase II Clinical Study

Table 3

Treatment responses.

Index	Total no.	Scheme 1	Scheme 2
No. of patients	33	6	27
Complete response (CR)	6 (18%)	1 (17%)	5 (19%)
Partial response (PR)	8 (24%)	1 (17%)	7 (26%)
Stable disease (SD)	14 (42%)	3 (50%)	11 (41%)
Progressive disease (PD)	5 (15%)	1 (17%)	4 (15%)
Objective response rate (ORR)	14 (42%)	2 (33%)	12 (44%)
Disease control rate (DCR)	28 (84%)	5 (83%)	23 (85%)